financetom
Business
financetom
/
Business
/
Lululemon Fiscal First-Quarter Earnings May Miss Views, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lululemon Fiscal First-Quarter Earnings May Miss Views, Oppenheimer Says
Jun 4, 2024 12:01 PM

02:36 PM EDT, 06/04/2024 (MT Newswires) -- Lululemon Athletica ( LULU ) may miss fiscal first-quarter earnings expectations on Wednesday, though trends have stabilized and the stock has already absorbed much of the near-term impact, according to Oppenheimer.

The brokerage on Tuesday reiterated its earnings per share target of $2.35 that suggests a 3% year-over-year gain from $2.28 the year earlier. Wall Street is expecting EPS of $2.40, while Lululemon's guidance ranges from $2.35 to $2.40, the report showed.

Oppenheimer is modeling for net revenue growth of 9.8% for the April quarter, which is below the consensus view's 9.9% growth rate but toward the upper-end of management's 9% to 10% guidance.

"While we do not expect an 'all-clear'-type report from (Lululemon), we do anticipate signals suggesting that trends at the brand have largely stabilized, lately," a group of Oppenheimer analysts including Brian Nagel said in a report.

Lululemon's "subdued initial" fiscal 2024 top-line growth guidance of 11% to 12%, which implies a deceleration from 2023's 19% revenue gain, isn't expected to be meaningfully adjusted on Wednesday, according to Nagel. Oppenheimer is guiding for full-year earnings per share of $14.01 on 11.2% revenue growth for the ongoing year, which is below the Street's $14.13 EPS estimate and 11.9% revenue forecast. Lululemon in March guided for full-year EPS in the $14 to $14.20 range.

Oppenheimer has removed the athletic apparel from its "top pick" list but the analysts said the shares are "well positioned" over the intermediate to long-term.

"While a fresh cloud of uncertainty now hangs over (Lululemon), underlying growth dynamics for the brand appear intact, improved innovation and marketing should bolster sales expansion, at least somewhat, nearer-term, and share valuations are tracking at historic troughs," Nagel said.

Shares of Lululemon have dropped more than 35% since the company's last earnings report in March, meaningfully underperforming the S&P 500's 1% decline, the report showed. Oppenheimer reiterated an outperform rating and a $445 12- to 18-month price target on the stock, implying more than 45% upside from current levels.

Price: 307.35, Change: +0.73, Percent Change: +0.24

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Knightscope Receives Contracts for Security Robots, Emergency Communication Devices
Knightscope Receives Contracts for Security Robots, Emergency Communication Devices
Mar 10, 2025
10:48 AM EDT, 03/10/2025 (MT Newswires) -- Knightscope ( KSCP ) said Monday it renewed four autonomous security robot subscription agreements, deployed seven autonomous security robots, and signed new sales contracts for 96 of its emergency communication devices. The security robot renewals were for customers in the healthcare, automotive lubricants, and logistics sectors, the company said. New deployments were for...
BRIEF-Avalon Globocare and Yoov to merge
BRIEF-Avalon Globocare and Yoov to merge
Mar 10, 2025
March 10 (Reuters) - Avalon Globocare Corp ( ALBT ): * AVALON GLOBOCARE AND YOOV, A LEADING BUSINESS AI AUTOMATION SOLUTIONS PROVIDER, ENTER INTO MERGER AGREEMENT * AVALON GLOBOCARE CORP ( ALBT ) - NEW COMBINED COMPANY TO TRADE UNDER NASDAQ SYMBOL 'YOOV' * AVALON GLOBOCARE CORP ( ALBT ) - PHIL WONG TO BECOME CHAIRMAN, CEO, AND PRESIDENT POST-MERGER...
Genmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall
Genmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall
Mar 10, 2025
10:58 AM EDT, 03/10/2025 (MT Newswires) -- Genmab ( GMAB ) said Monday that Johnson & Johnson ( JNJ ) has chosen not to exercise its option for a global license to develop, produce, and market HexaBody-CD38. Although the initial HexaBody-CD38 clinical data demonstrated strong efficacy, Genmab ( GMAB ) has decided not to proceed with further development after evaluating...
SunCar Gets Contract to Build Insurance Platform for Leapmotor
SunCar Gets Contract to Build Insurance Platform for Leapmotor
Mar 10, 2025
10:54 AM EDT, 03/10/2025 (MT Newswires) -- SunCar Technology Group ( SDA ) said Monday it has secured a contract to develop and operate an insurance management platform for electric vehicle maker Leapmotor. This contract transforms our relationship with Leapmotor from service provider to technology partner, said Chief Executive Officer Ye Zaichang. The system will be integrated into Leapmotor's mobile...
Copyright 2023-2026 - www.financetom.com All Rights Reserved